A key advisory group vows to base decisions on evidence, boost confidence in vaccines and protect health. Experts fear the opposite is happening.

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

Dr. Todd Ellerin, Vice Chair of Department of Medicine of South Shore Health discusses the new FDA warning regarding Pfizer ...

The Trump administration is continuing to make its imprint on U.S. vaccine policy in recent days. The moves could change what ...

A CDC advisory panel voted 5–1 to recommend only flu vaccines without the preservative thimerosal, a mercury-containing ...

A CDC panel’s vote to stop recommending thimerosal-containing flu shots would have limited impact, but it illustrates how the anti-vaccine movement is achieving its goals.